Quick Answer
HALOZYME THERAPEUTICS, INC. reported Long Term Debt of $2.14 billion for the year ending 2025.
- HALOZYME THERAPEUTICS, INC. showed an increase of +42.3% in Long Term Debt from 2024 to 2025.
- This data is from HALOZYME THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2011 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: $28.32 million | Q2 2013: $26.08 million | Q3 2013: $23.78 million | Q1 2014: $47.39 million | Q2 2014: $43.61 million | Q3 2014: $39.76 million | Q1 2015: $45.99 million | Q2 2015: $40.10 million | Q3 2015: $34.09 million | Q1 2016: $168.60 million | Q2 2016: $204.85 million | Q3 2016: $199.80 million | Q1 2017: $184.43 million | Q2 2017: $165.52 million | Q3 2017: $145.42 million | Q1 2018: $102.70 million | Q2 2018: $79.08 million | Q3 2018: $57.94 million | Q1 2019: $18.74 million | Q2 2019: $14.08 million | Q3 2019: $9.31 million | Q1 2020: $386.57 million | Q2 2020: $390.08 million | Q3 2020: $393.63 million | Q1 2021: $784.73 million | Q2 2021: $785.57 million | Q3 2021: $786.45 million | Q4 2021: $787.26 million | Q1 2022: $788.10 million | Q2 2022: $1.15 billion | Q3 2022: $1.49 billion | Q1 2023: $1.49 billion | Q2 2023: $1.50 billion | Q3 2023: $1.50 billion | Q1 2024: $1.50 billion | Q2 2024: $1.50 billion | Q3 2024: $1.50 billion | Q1 2025: $1.51 billion | Q2 2025: $1.51 billion | Q3 2025: $800.07 million.
- Historical annual values: Fiscal year 2025: $2.14 billion | Fiscal year 2024: $1.51 billion | Fiscal year 2023: $1.50 billion | Fiscal year 2022: $1.49 billion | Fiscal year 2022: $1.49 billion | Fiscal year 2021: $787.26 million | Fiscal year 2020: $0.00 | Fiscal year 2019: $383.05 million | Fiscal year 2018: $34.87 million | Fiscal year 2017: $125.14 million | Fiscal year 2016: $199.23 million | Fiscal year 2015: $27.97 million | Fiscal year 2014: $49.86 million | Fiscal year 2013: $49.77 million | Fiscal year 2012: $29.66 million | Fiscal year 2011: $0.00.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: